These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36424024)

  • 41. Ibuprofen: pharmacology, efficacy and safety.
    Rainsford KD
    Inflammopharmacology; 2009 Dec; 17(6):275-342. PubMed ID: 19949916
    [TBL] [Abstract][Full Text] [Related]  

  • 42. COX-2 selective inhibitors in the treatment of osteoarthritis.
    Laine L; White WB; Rostom A; Hochberg M
    Semin Arthritis Rheum; 2008 Dec; 38(3):165-87. PubMed ID: 18177922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.
    Stiller CO; Hjemdahl P
    J Intern Med; 2022 Oct; 292(4):557-574. PubMed ID: 35585779
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.
    Martelli A; Testai L; Anzini M; Cappelli A; Di Capua A; Biava M; Poce G; Consalvi S; Giordani A; Caselli G; Rovati L; Ghelardini C; Patrignani P; Sautebin L; Breschi MC; Calderone V
    Pharmacol Res; 2013 Dec; 78():1-9. PubMed ID: 24083950
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Pharmacology and Cardiovascular Safety of Naproxen.
    Angiolillo DJ; Weisman SM
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):97-107. PubMed ID: 27826802
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks.
    Cairns JA
    Can J Cardiol; 2007 Feb; 23(2):125-31. PubMed ID: 17311118
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
    Stillman MJ; Stillman MT
    Geriatrics; 2007 Mar; 62(3):16-21. PubMed ID: 17346094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs.
    Mosis G; Stijnen T; Castellsague J; Dieleman JP; van der Lei J; Stricker BH; Sturkenboom MC
    Arthritis Rheum; 2006 Aug; 55(4):537-42. PubMed ID: 16874797
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclo-oxygenase-2 inhibitors : beneficial or detrimental for athletes with acute musculoskeletal injuries?
    Warden SJ
    Sports Med; 2005; 35(4):271-83. PubMed ID: 15831058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users.
    Laharie D; Droz-Perroteau C; Bénichou J; Amouretti M; Blin P; Bégaud B; Guiard E; Dutoit S; Lamarque S; Moride Y; Depont F; Fourrier-Réglat A; Moore N
    Br J Clin Pharmacol; 2010 Mar; 69(3):295-302. PubMed ID: 20233201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Benefits and Risks of Nonsteroidal Anti-inflammatory Drugs: Methodologic Limitations Lead to Clinical Uncertainties.
    Rane MA; Foster JG; Wood SK; Hebert PR; Hennekens CH
    Ther Innov Regul Sci; 2019 Jul; 53(4):502-505. PubMed ID: 30176739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recategorization of Non-Aspirin Nonsteroidal Anti-inflammatory Drugs According to Clinical Relevance: Abandoning the Traditional NSAID Terminology.
    Bonnesen K; Schmidt M
    Can J Cardiol; 2021 Nov; 37(11):1705-1707. PubMed ID: 34182020
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice.
    Ho KY; Gwee KA; Cheng YK; Yoon KH; Hee HT; Omar AR
    J Pain Res; 2018; 11():1937-1948. PubMed ID: 30288088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
    Borer JS; Simon LS
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial.
    Ruschitzka F; Borer JS; Krum H; Flammer AJ; Yeomans ND; Libby P; Lüscher TF; Solomon DH; Husni ME; Graham DY; Davey DA; Wisniewski LM; Menon V; Fayyad R; Beckerman B; Iorga D; Lincoff AM; Nissen SE
    Eur Heart J; 2017 Nov; 38(44):3282-3292. PubMed ID: 29020251
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular risk of non-steroidal anti-inflammatory drugs.
    Alušík Š; Paluch Z
    Vnitr Lek; 2018; 64(3):266-271. PubMed ID: 29766729
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.